Compare ASIX & AQST Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ASIX | AQST |
|---|---|---|
| Founded | 2016 | 2004 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Chemicals | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 527.0M | 504.0M |
| IPO Year | 2016 | 2007 |
| Metric | ASIX | AQST |
|---|---|---|
| Price | $23.06 | $4.15 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 2 | 5 |
| Target Price | ★ $26.00 | $9.00 |
| AVG Volume (30 Days) | 450.0K | ★ 1.3M |
| Earning Date | 05-01-2026 | 05-11-2026 |
| Dividend Yield | ★ 2.75% | N/A |
| EPS Growth | ★ 11.11 | N/A |
| EPS | ★ 1.80 | N/A |
| Revenue | ★ $1,684,625,000.00 | $67,430,000.00 |
| Revenue This Year | $4.19 | $10.08 |
| Revenue Next Year | $4.60 | $49.60 |
| P/E Ratio | $12.97 | ★ N/A |
| Revenue Growth | ★ 45.49 | 0.77 |
| 52 Week Low | $14.10 | $2.22 |
| 52 Week High | $25.94 | $7.55 |
| Indicator | ASIX | AQST |
|---|---|---|
| Relative Strength Index (RSI) | 52.43 | 52.45 |
| Support Level | $20.28 | $3.70 |
| Resistance Level | $25.74 | $4.32 |
| Average True Range (ATR) | 0.92 | 0.13 |
| MACD | -0.30 | 0.01 |
| Stochastic Oscillator | 0.83 | 61.11 |
AdvanSix Inc is a diversified chemistry company playing a critical role in international supply chains, innovating and delivering essential products for customers across a wide variety of end markets and applications that touch people's lives, including building and construction, fertilizers, agrochemicals, plastics, solvents, packaging, paints, coatings, adhesives, and electronics. The company's key products include Nylon, Caprolactam, Plant Nutrients, and Chemical Intermediates. The majority of sales are from Plant Nutrients products. The company operates in the United States and internationally, with the majority of revenue coming from the United States.
Aquestive Therapeutics Inc is a specialty pharmaceutical company engaged in developing and commercializing differentiated products to meet medical needs. Its later-stage product pipeline focuses on the treatment of diseases of the Central Nervous System (CNS), and an earlier-stage pipeline for the treatment of severe allergic reactions, including anaphylaxis. Its commercial product portfolio includes Suboxone, Emylif, Ondif, and Sympazan. The product pipeline includes Libervant Buccal Film, AQST-108. The majority of its revenue comes from the United States.